Literature DB >> 26514836

Association between antidepressants and falls in Parkinson's disease.

Daniel Martinez-Ramirez1, Juan C Giugni2, Leonardo Almeida2, Roger Walz2, Bilal Ahmed2, Fiona A Chai2, Valerie Rundle-Gonzalez2, Alberto R Bona2, Erin Monari2, Aparna Wagle Shukla2, Christopher W Hess2, Chris J Hass3, Michael S Okun2,4.   

Abstract

Parkinson's disease (PD) patients have an increased risk of falls resulting in important social and economical consequences. Risk factors for falls include the use of psychotropic drugs, which are used for the treatment of PD neuropsychiatric symptoms. We aimed to determine the association between psychotropic drug use and falls in a PD cohort. A cross-sectional study from the NPF QII study UF site was conducted. Subjects reported presence and frequency of falls in the prior year. Frequency was scored from 0 (no falls) to 4 (falling daily). Antidepressants, antipsychotics, cognitive enhancers/stimulants, and benzodiazepines were considered psychotropics. Forty percent of the 647 subjects included had a fall in the previous year. Fallers were found to have clinical signs of a more advanced disease. After adjusting for confounding variables, the regression analysis showed that use of antidepressants alone (adjusted OR 2.2, CI 95 % 1.3-3.8, p = 0.04), benzodiazepines alone (adjusted OR 2.0, CI 95 % 1.1-3.5, p = 0.02), and the combination of antidepressants with benzodiazepines (adjusted OR 4.1, CI 95 % 2.0-8.3, p < 0.0001) were independently associated with the presence of falls. When comparing to those not on psychotropics, subjects on antidepressants alone had a significantly higher mean frequency of falls score (1.07 vs. 0.44, p < 0.0001). The use of antidepressants was independently associated with falls in our PD cohort after considering for confounding variables such as age and measures of disease progression. Other factors related to disease progression should be considered before claiming the use of psychotropic drugs as causative.

Entities:  

Keywords:  Falls; Neuroleptics; Nootropics; Psychotropics; Stimulants

Mesh:

Substances:

Year:  2015        PMID: 26514836     DOI: 10.1007/s00415-015-7947-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  26 in total

Review 1.  Gait disorders and balance disturbances in Parkinson's disease: clinical update and pathophysiology.

Authors:  Tjitske A Boonstra; Herman van der Kooij; Marten Munneke; Bastiaan R Bloem
Journal:  Curr Opin Neurol       Date:  2008-08       Impact factor: 5.710

2.  Risks associated with long-term benzodiazepine use.

Authors:  Brian Johnson; Jon Streltzer
Journal:  Am Fam Physician       Date:  2013-08-15       Impact factor: 3.292

3.  Prospective assessment of falls in Parkinson's disease.

Authors:  B R Bloem; Y A Grimbergen; M Cramer; M Willemsen; A H Zwinderman
Journal:  J Neurol       Date:  2001-11       Impact factor: 4.849

4.  Falls in Parkinson disease: analysis of a large cross-sectional cohort.

Authors:  Sotirios A Parashos; Catherine L Wielinski; Nir Giladi; Tanya Gurevich
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568

5.  Different risk-increasing drugs in recurrent versus single fallers: are recurrent fallers a distinct population?

Authors:  Marjan Askari; Saied Eslami; Alice C Scheffer; Stephanie Medlock; Sophia E de Rooij; Nathalie van der Velde; Ameen Abu-Hanna
Journal:  Drugs Aging       Date:  2013-10       Impact factor: 3.923

6.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

7.  Piloting the NPF data-driven quality improvement initiative.

Authors:  Michael S Okun; Andrew Siderowf; John G Nutt; Gerald T O'Conner; Bastiaan R Bloem; Elaine M Olmstead; Mark Guttman; Tanya Simuni; Eric Cheng; Elaine V Cohen; Sotirios Parashos; Laura Marsh; Irene A Malaty; Nir Giladi; Peter Schmidt; Joyce Oberdorf
Journal:  Parkinsonism Relat Disord       Date:  2010-07-06       Impact factor: 4.891

8.  Longitudinal outcome of Parkinson's disease patients with psychosis.

Authors:  S A Factor; P J Feustel; J H Friedman; C L Comella; C G Goetz; R Kurlan; M Parsa; R Pfeiffer
Journal:  Neurology       Date:  2003-06-10       Impact factor: 9.910

9.  A meta-analysis of six prospective studies of falling in Parkinson's disease.

Authors:  Ruth M Pickering; Yvette A M Grimbergen; Una Rigney; Ann Ashburn; Gordon Mazibrada; Brian Wood; Peggy Gray; Graham Kerr; Bastiaan R Bloem
Journal:  Mov Disord       Date:  2007-10-15       Impact factor: 10.338

10.  A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson's disease patients without dementia.

Authors:  A McKinlay; R C Grace; J C Dalrymple-Alford; T Anderson; J Fink; D Roger
Journal:  Parkinsonism Relat Disord       Date:  2007-07-12       Impact factor: 4.891

View more
  6 in total

Review 1.  Assessment and Management of Neuropsychiatric Symptoms in Parkinson's Disease.

Authors:  Christoph Mueller; Anto P Rajkumar; Yi Min Wan; Latha Velayudhan; Dominic Ffytche; Kallol Ray Chaudhuri; Dag Aarsland
Journal:  CNS Drugs       Date:  2018-07       Impact factor: 5.749

2.  Sleep and affective disorders in relation to Parkinson's disease risk among older women from the Women's Health Initiative.

Authors:  Hind A Beydoun; Jiu-Chiuan Chen; Nazmus Saquib; Michelle J Naughton; May A Beydoun; Aladdin H Shadyab; Lauren Hale; Alan B Zonderman
Journal:  J Affect Disord       Date:  2022-06-22       Impact factor: 6.533

3.  Interdisciplinary Parkinson's Disease Deep Brain Stimulation Screening and the Relationship to Unintended Hospitalizations and Quality of Life.

Authors:  Masa-Aki Higuchi; Daniel Martinez-Ramirez; Hokuto Morita; Dan Topiol; Dawn Bowers; Herbert Ward; Lisa Warren; Meredith DeFranco; Julie A Hicks; Karen W Hegland; Michelle S Troche; Shankar Kulkarni; Erin Hastings; Kelly D Foote; Michael S Okun
Journal:  PLoS One       Date:  2016-05-09       Impact factor: 3.240

4.  Prioritising target non-pharmacological interventions for research in Parkinson's disease: achieving consensus from key stakeholders.

Authors:  Angeliki Bogosian; Lorna Rixon; Catherine S Hurt
Journal:  Res Involv Engagem       Date:  2020-06-24

5.  Do Benzodiazepines Impair Motor and Nonmotor Symptoms in a Sample of Parkinson's Disease Patients?

Authors:  Wendy Gaztanaga; Marina Sarno; Jason Margolesky; Corneliu Luca; Carlos Singer; Henry Moore; Jonathan Jagid; Bonnie Levin
Journal:  Cureus       Date:  2021-02-08

6.  Psychotropic medication use and Parkinson's disease risk amongst older women.

Authors:  Hind A Beydoun; Nazmus Saquib; Robert B Wallace; Jiu-Chiuan Chen; Mace Coday; Michelle J Naughton; May A Beydoun; Aladdin H Shadyab; Alan B Zonderman; Robert L Brunner
Journal:  Ann Clin Transl Neurol       Date:  2022-06-24       Impact factor: 5.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.